<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">REVHEIM, MONA-ELISABETH</style></author><author><style face="normal" font="default" size="100%">SEIERSTAD, THERESE</style></author><author><style face="normal" font="default" size="100%">BERNER, JEANNE-MARIE</style></author><author><style face="normal" font="default" size="100%">BRULAND, ØYVIND SVERRE</style></author><author><style face="normal" font="default" size="100%">RØE, KATHRINE</style></author><author><style face="normal" font="default" size="100%">OHNSTAD, HEGE OMA</style></author><author><style face="normal" font="default" size="100%">BJERKEHAGEN, BODIL</style></author><author><style face="normal" font="default" size="100%">BACH-GANSMO, TORE</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Establishment and Characterization of a Human Gastrointestinal Stromal Tumour (GIST) Xenograft in Athymic Nude Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4331-4336</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">11</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The majority of gastrointestinal stromal tumours (GISTs) contain oncogenic KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) or platelet-derived growth factor-alpha (PDGFRA) receptor tyrosine kinase (TK) mutations and are initially, but only temporarily sensitive to TK inhibitors. The aim of this study was to establish and characterize a human GIST xenograft that could be used for evaluating various molecularly targeted therapies. Materials and Methods: GIST tissue from four patients was implanted under the skin of athymic nude mice. In one case a tumour line was established. Results: The xenograft showed characteristic GIST morphology and exhibited the same mutation profile as that of the patient. Conclusion: A human GIST xenograft with mutation in KIT exons 11 and 17 has been established and maintained in nude mice for 3 years (13 passages). This model will enable further studies on mechanisms of resistance, combination therapies and allow testing of novel targeted therapies.</style></abstract></record></records></xml>